Indications for H. pylori Testing
Test all patients with peptic ulcer disease (active or past), gastric MALT lymphoma, gastric cancer, uninvestigated dyspepsia under age 50 without alarm symptoms, first-degree relatives of gastric cancer patients, and those requiring long-term NSAID therapy who are NSAID-naive. 1, 2, 3
Primary Testing Indications
Established High-Priority Indications
These patients should always be tested:
- Peptic ulcer disease (active or history of) - H. pylori causes the majority of peptic ulcers and eradication prevents recurrence 1, 3, 4
- Gastric MALT lymphoma - H. pylori eradication can lead to lymphoma regression 3, 4
- Gastric adenocarcinoma (non-cardia) - both for treatment and prevention 1, 3
- First-degree relatives of gastric cancer patients - they have nearly 2-fold increased risk of H. pylori infection and premalignant gastric changes 5
Dyspepsia Management Strategy
For patients under age 50 with uninvestigated dyspepsia and no alarm symptoms, use a "test-and-treat" strategy with non-invasive testing 1, 2. This approach is safe, cost-effective, and reduces unnecessary endoscopy. The evidence strongly supports this as first-line management in primary care 1, 6.
For patients over age 50 or those with alarm symptoms (bleeding, weight loss, dysphagia, persistent vomiting), proceed directly to endoscopy with biopsy-based testing 2.
NSAID-Related Indications
Test NSAID-naive patients who require long-term NSAID therapy 3. H. pylori eradication before starting NSAIDs prevents peptic ulcer development 4. This is a proactive, evidence-based strategy to reduce morbidity.
Testing Methods Based on Clinical Context
Non-Invasive Testing (Preferred for Most Outpatients)
Use urea breath test or stool antigen test - these are the two most accurate non-invasive methods 1.
Critical caveat: Stop proton pump inhibitors at least 1-2 weeks before testing to avoid false-negative results 3, 4, 7.
Avoid serology for active infection diagnosis - antibodies persist long after eradication, leading to false positives with only 78% overall accuracy 1. Serology is only useful for epidemiologic studies, not clinical decision-making 1.
Invasive Testing (When Endoscopy is Performed)
Use rapid urease test, histology, or culture when endoscopy is indicated 1, 3. Taking biopsies from both antrum and body increases sensitivity substantially 2.
Consider culture with antibiotic sensitivity testing after second-line treatment failure to guide subsequent therapy 8, 9.
Post-Treatment Confirmation
All patients require confirmation of eradication after treatment, but this is mandatory for:
- Peptic ulcer disease
- Gastric cancer
- MALT lymphoma 3
Use urea breath test or stool antigen test at least 4 weeks after completing therapy 3, 7. Do not use serology for post-treatment testing - it remains positive for 6-12 months after successful eradication 7.
Emerging Indications
Gastric cancer prevention in H. pylori gastritis - Recent guidelines support testing for eradication to prevent progression to gastric cancer, particularly in high-risk populations 5, 10. H. pylori is classified as a Class I carcinogen 1.
Regression of gastric hyperplastic polyps ≤10mm - New evidence supports testing and treatment 10.
Common Pitfalls to Avoid
- Do not test patients currently taking PPIs without stopping them first - this causes false-negatives 3, 4
- Do not use serology for diagnosis in clinical practice - inadequate accuracy and cannot distinguish active from past infection 1
- Do not skip post-eradication testing - treatment failure rates are significant, especially with rising antibiotic resistance 8, 10
- Do not test patients over 50 with new dyspepsia non-invasively - they need endoscopy to exclude malignancy 2